echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The management of two multinational pharmaceutical companies has changed on March 1st!

    The management of two multinational pharmaceutical companies has changed on March 1st!

    • Last Update: 2021-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▌ The two business units of Fessen and Huarui merged

    According to Dami’s understanding, today, Fresenius Kabi China announced to employees that since March 1st, the Anesthesia and Surgery Division of Beijing Fresenius Kabi Pharmaceutical Co.


    The two business units merged into a new "Parenteral Nutrition and Anesthesia Division", and Chen Guang was appointed as the Vice President of Fresenius Kabi China, who is fully responsible for the business operations and personnel management of the new Parenteral Nutrition and Anesthesia Division.


    Chen Guang is currently the executive deputy general manager of Fika Huarui.


    After this new appointment, Chen Guang will still serve as the executive deputy general manager of Fika Huarui, reporting to the general manager of Fika Huarui Zhuang Wenyan.


    Of course, like other multinational pharmaceutical companies in China, Fresenius Kabi’s adjustment is also to adapt to changes in national pharmaceutical policies, optimize product portfolios, and improve operational efficiency.


    The German Fresenius Group is a large multinational medical enterprise, composed of four independent business units, which are responsible for their respective global operations: including Fresenius Medical Products Company, Fresenius Kabi, and Fresenius Schilius and Fresenius Omed.


    Among them, Fresenius Kabi is a multinational enterprise specializing in the field of infusion, blood transfusion and clinical nutrition.


    As early as the 1980s, Fresenius Kabi started its business in China.


    Fika Huarui's predecessor, Huarui Pharmaceutical, was established in 1982.


    At the beginning of 2016, Beifei and Huarui began preparations for a merger in Beijing.


    ▌ Ji Cheng was transferred to the head of Novartis Pharmaceuticals (China) Hong Kong

    Not only Fresenius Kabi, but Dami understands that the management staff of Novartis, another multinational pharmaceutical company, will also change next month.


    Yesterday, Novartis Pharmaceuticals announced that it had appointed Ji Cheng as the head of Novartis Pharmaceuticals (China) Hong Kong, reporting directly to Wang Jia, the head of Novartis Pharmaceuticals (China) Transplantation and Respiratory Division.


    Ji Cheng is currently the head of Novartis Pharmaceuticals (China) business model transformation promotion and digitalization team.


    After Ji Cheng was transferred to Hong Kong, his successor has not yet been determined.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.